Top-News

Galapagos Aktie News

Aktie
WKN:  A0EAT9 ISIN:  BE0003818359 US-Symbol:  GLPGF Branche:  Biotechnologie Land:  Belgien
27,14 €
-0,16 €
-0,59%
05.12.25
Depot/Watchlist
Marktkapitalisierung *
1,77 Mrd. €
Streubesitz
42,50%
KGV
-21,88
Index-Zuordnung
-
Weiter abwärts? Short handeln - Jetzt mit Hebel 6,00: JZ07Q7
Werbung

Galapagos News

26.11.25 - GlobeNewswire
Galapagos Receives Transparency Notifications from Bank of America
Mechelen, Belgium ; November 26, 2025, 07:30 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received transparency notifications from Bank of America.
05.11.25 - GlobeNewswire
Galapagos Reports Nine Months 2025 Financial Results and Provides Business Update
Strategic review process concluded with intention to wind down cell therapy business, representing optimal capital allocation pathway to support a stronger and sustainable future ...
03.11.25 - GlobeNewswire
Galapagos to Present New Data from Cell Therapy Program at ASH 2025
Oral presentation of GLPG5101 data from the ATALANTA-1 study in patients with high-risk relapsed/refractory mantle cell lymphoma
30.10.25 - GlobeNewswire
Galapagos Announces Changes to its Board to Accelerate Strategic Focus on Business Development
New Directors bring strong financial leadership, capital allocation, and business development expertise to the Board Mechelen, Belgium; October 30, 2025, 21:01 CET — Galapagos ...
23.10.25 - GlobeNewswire
Galapagos to Present In Vitro Data at ACR Convergence 2025 Suggesting Differentiation of GLPG3667 from Other TYK2 Inhibitors
Mechelen, Belgium ; October 23, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present new in vitro pharmacological data from its ...
21.10.25 - GlobeNewswire
Galapagos Announces Intention to Wind Down Cell Therapy Business as Part of the Company’s Ongoing Transformation
Intention follows comprehensive strategic review process and would represent the optimal capital allocation pathway to support a stronger and sustainable future for Galapagos ...
16.10.25 - GlobeNewswire
Galapagos Announces Appointment of Fred Blakeslee as General Counsel
Mechelen, Belgium ; October 16, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced the appointment of Mr. Fred Blakeslee as Executive Vice President ...
01.10.25 - GlobeNewswire
Galapagos Provides Update on Strategic Alternatives for Its Cell Therapy Business  
Mechelen, Belgium ; October 1, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) and its Board of Directors today issued the following statement: On May 13, 2025, ...
07.08.25 - GlobeNewswire
Galapagos Creates New Subscription Right Plan
Mechelen, Belgium; August 7, 2025, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its  Board of Directors created 1,800,000 s...
06.08.25 - GlobeNewswire
Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to GLPG5101 for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
Mechelen, Belgium; August 6, 2025, 7:30 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the United States Food ...
23.07.25 - GlobeNewswire
Galapagos Bolster Leadership Team with Seasoned Life Sciences Executives to Accelerate Business Transformation
Appoints Sooin Kwon as Chief Business Officer and Dan Grossman as Chief Strategy Officer Both executives possess proven track records in strategic execution and deal-​making ...
23.07.25 - GlobeNewswire
Galapagos Welcomes Seasoned Pharmaceutical Executives Dawn Svoronos and Jane Griffiths to Its Board of Directors
New Directors bring deep commercial, operational, and transaction experience to the Board Mechelen, Belgium; July 23, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ ...
23.07.25 - GlobeNewswire
Galapagos Reports Half-Year 2025 Financial Results and Provides Second Quarter Business Update
Appointments of new CEO, CFO, and seasoned business development leaders with proven track records of executing strategic transactions will position the Company to drive ...
23.06.25 - GlobeNewswire
Galapagos Appoints Aaron Cox as Chief Financial Officer
Former Horizon CFO joins Galapagos with deep expertise in international corporate finance, M&A, business development and strategic leadership  Mechelen, Belgium; June 23, ...
18.06.25 - GlobeNewswire
Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity Rates With CAR-T Candidate GLPG5101
Of the 34 patients enrolled in Cohort 3 of the ATALANTA-1 Phase 1/2 study, 32 received GLPG5101; 94% were infused with fresh CAR-T cells, and 93% were treated within seven ...
12.06.25 - GlobeNewswire
Galapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighting Low Toxicity and Rapid, Decentralized Delivery of Fresh, Early-Memory-Enriched GLPG5101 in R/R NHL
Data reported from the ongoing ATALANTA-1 Phase 1/2 study in a heavily pretreated relapsed refractory non-​Hodgkin’s Lymphoma (R/R NHL) patient population demonstrate low ...
27.05.25 - GlobeNewswire
Galapagos Creates New Subscription Right Plan
Mechelen, Belgium;  May 27, 2025, 22:30 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its  Board of Directors created 925,000 ...
14.05.25 - GlobeNewswire
Galapagos Announces Oral Presentations at EHA and ICML 2025 Featuring Promising New Data from ATALANTA-1 study of Investigational CAR-T Candidate GLPG5101
Mechelen, Belgium; May 14, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-...
13.05.25 - GlobeNewswire
Galapagos Announces Strategic Update on Proposed Separation, Executive Leadership Transition and Board Changes
Galapagos to re-​evaluate the implementation of the previously announced separation following regulatory and market developments Galapagos to explore all strategic alternatives ...
23.04.25 - GlobeNewswire
Galapagos Reports First Quarter 2025 Financial Results, Recent Business Highlights and Near-Term Catalysts
First U.S. patient dosed in ATALANTA-1 study of GLPG5101

Newssuche

Videos

newspaper
05.12.25 +1,73%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »